Pharmaceutical manufacturer Pharmaron's Cramlington base set for investment despite losses
Losses have narrowed at Cramlington's Pharmaron amid a year of continued investment in the site.
New results for the Chinese-owned business - formerly called Aesica - show operating losses fell from £24.4m to £13.7m in 2023 as revenues rose from £5.09m to £7.48m. Bosses said the Windmill Industrial Estate firm, which specialises in the production of active pharmaceutical ingredients, has the backing of its parent company, Beijing-based life sciences giant Pharmaron, in planned expansion.
The firm has posted operating losses since 2020 when it suffered a temporary shutdown of all production owing to a "significant, unexpected incident". But that has not stopped Pharmaron, which acquired the facility in early 2022, from eyeing development of the site, which employs about 140 people.
Read more: ScS boss Steve Carson to step down having steered retailer through Italian takeover
Read more: Next Page
